TTR and cardiomyopathy: The 2023 European Society of Cardiology (ESC) Guidelines on Cardiomyopathies[21] state that DPD/PYP/HMDP SPECT myocardial imaging is the gold standard fordiagnosing ATTR-CA and it may obviate the need for myocardial biopsy.Additionally, novel amyloid-targeted PET tracers such as 11C-Pittsburghcompound-B (11C-PIB), 18F-florbetapir, 18F-flutemetamol, and18F-florbetaben, specifically bind to the β-sheet structure ofamyloid proteins and are suitable for detecting both AL and ATTR subtypes [26, 27].